Tolerability/safety of sunitinib (SU) on schedule 2/1 in combination with capecitabine (C) in patients (pts) with advanced solid tumors (STs): A phase I dose-finding study

被引：1
|
作者：
Chiorean, E. G.
Sweeney, C. J.
Verschraegen, C. F.
Lee, F. C.
Jones, S. F.
Rabinowitz, I.
Tye, L.
Bello, A.
Chao, R.
Burris, H. A., III
机构：
[1] Univ New Mexico, Albuquerque, NM 87131 USA
[2] Indiana Univ, Indianapolis, IN 46204 USA
[3] Sarah Cannon Res Inst, Nashville, TN USA
[4] Pfizer Global Res & Dev, La Jolla, CA USA
[5] Pfizer Inc, New York, NY USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2008年 / 26卷 / 15期
关键词：
D O I：
10.1200/jco.2008.26.15_suppl.3562
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
3562
引用
收藏
页数：1
相关论文
共 50 条
  • [21] A phase I dose escalation study of sunitinib plus capecitabine in patients with advanced solid tumors
    Sweeney, C.
    Verschraegen, C.
    Chiorean, G.
    Lee, F.
    Jones, S.
    Tye, L.
    Bello, A.
    Chao, R.
    Burris, H., III
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [22] A phase I study evaluating administration of oral SU11248 (sunitinib malate) using a loading and maintenance dose on a 2/1 schedule in patients (pts) with advanced solid tumors
    Rosen, Lee S.
    Bello, Carlo L.
    Mulay, Marilyn
    Dinolfo, Melissa
    Baum, Charles
    CANCER RESEARCH, 2006, 66 (08)
  • [23] A Phase I Study of Sunitinib Plus Capecitabine in Patients With Advanced Solid Tumors
    Sweeney, Christopher J.
    Chiorean, E. Gabriela
    Verschraegen, Claire F.
    Lee, Fa Chyi
    Jones, Suzanne
    Royce, Melanie
    Tye, Lesley
    Liau, Katherine F.
    Bello, Akintunde
    Chao, Richard
    Burris, Howard A.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (29) : 4513 - 4520
  • [24] A PHASE I, DOSE-FINDING STUDY OF SUNITINIB (SU) IN COMBINATION WITH CISPLATIN (P) AND 5-FLUOROURACIL (5-FU) IN PATIENTS (PTS) WITH ADVANCED GASTRIC CANCER (GC)
    Gomez-Martin, C.
    Gil-Martin, M.
    Montagut, C.
    Nunez, J. A.
    Salazar, R.
    Puig, M.
    Khosravan, R.
    Tursi, J. M.
    Lechuga, M. J.
    Bellmunt, J.
    ANNALS OF ONCOLOGY, 2010, 21 : 255 - 255
  • [25] A phase I study of vorinostat (VOR) in combination with capecitabine (CAP) in patients (pts) with advanced solid tumors
    Tang, P.
    Oza, A.
    Townsley, C.
    Siu, L.
    Pond, G.
    Sarveswaran, P.
    Webster, S.
    Zwiebel, J.
    Chen, E.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [26] A phase I dose-finding, safety and tolerability study of AZD8330 in patients with advanced malignancies
    Cohen, Roger B.
    Aamdal, Steinar
    Nyakas, Marta
    Cavallin, Maria
    Green, Darron
    Learoyd, Maria
    Smith, Ian
    Kurzrock, Razelle
    EUROPEAN JOURNAL OF CANCER, 2013, 49 (07) : 1521 - 1529
  • [27] Phase I dose-finding study of capecitabine (X) with escalating irinotecan (I) and oxaliplatin (O) in patients (pts) with previously treated solid tumors.
    Samanta, E
    Rigatos, SK
    Triantafillis, M
    Kourtis, S
    Koutsourakis, G
    Papanikitas, K
    Konstantinopoulou, A
    Koussoulas, V
    Aravantinos, G
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 256S - 256S
  • [28] Biweekly vinorelbine and gemcitabine:: a phase I dose-finding study in patients with advanced solid tumors
    Castellano, D
    Hitt, R
    Ciruelos, E
    Cortés-Funes, H
    Colomer, R
    ANNALS OF ONCOLOGY, 2003, 14 (05) : 783 - 787
  • [29] Phase I dose-finding and pharmacologic study of cisplatin (P), irinotecan (C), and either capecitabine (X) or infusional 5-FU (F) in patients (pts) with advanced solid tumors
    Enzinger, Peter C.
    Earle, Craig
    Zhu, Andrew
    Blaskowsky, Lawrence
    Kulke, Matthew
    Ryan, David
    Langford, Lauren
    Michelini, Ann
    Meyerhardt, Jeffrey
    ANNALS OF ONCOLOGY, 2004, 15 : 106 - 106
  • [30] A phase I dose-finding study of pemetrexed combined with paclitaxel in patients with advanced solid tumors
    Bolling, C.
    Luebbing, C.
    Graefe, T.
    Mueler-Hagen, S.
    Leisner, B.
    Blatter, J.
    Hanauske, A.-R.
    EJC SUPPLEMENTS, 2005, 3 (02): : 421 - 421
12345